Pre-Open Movers 08/17: (IZEA) (ZOES) (JWN) Higher; (ZN) (VNET) (DF) Lower (more...)
- Wall Street closes lower as inflation fears prompt tech sell-off
- Dogecoin Sees 'Sell the News' Reaction to Musk's SNL Appearance, as 'Hustle' Comment is Weighed Against Launch 'To the Moon'
- Alphabet (GOOGL) and Facebook (FB) Downgraded to 'Neutral' at Citi as Decelerating Growth Is Not Bullish for Multiples
- Elliott Management has stake in Duke Energy (DUK) - WSJ
- Ethereum (ETH) Soars Above $4,000 to Print Fresh Record Highs
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Today's Pre-Open Movers
IZEA, Inc. (NASDAQ: IZEA) 51.6% HIGHER; is reporting several large new contract wins thus far in Q3.
Zion Oil & Gas, Inc. (NASDAQ: ZN) 39% LOWER; announces that it is completing the initial testing program of its primary zones located within the Triassic-age Mohilla Formation of the Megiddo-Jezreel #1 (MJ #1) well.
Zoes Kitchen, Inc. (NYSE: ZOES) 34.1% HIGHER; announced that it has entered into a definitive agreement to be acquired in a transaction by privately held Cava Group, Inc., a fast-growing Mediterranean culinary brand with 66 restaurants. The combined companies will have 327 restaurants in 24 states throughout the U.S.
Nordstrom (NYSE: JWN) 13.3% HIGHER; reported Q2 EPS of $0.95, $0.11 better than the analyst estimate of $0.84. Revenue for the quarter came in at $4.07 billion versus the consensus estimate of $3.96 billion.
21Vianet Group (NASDAQ: VNET) 12.7% LOWER; reported Q2 EPS of ($0.12), $0.11 worse than the analyst estimate of ($0.01). Revenue for the quarter came in at $125.2 million versus the consensus estimate of $153.1 million.
Amyris, Inc. (Nasdaq: AMRS) 12.1% LOWER; announced the pricing of the previously announced underwritten secondary offering of approximately 7.65 million shares by certain of its existing stockholders (the selling stockholders) at the public offering price of $6.25 per share.
Adomani (NASDAQ: ADOM) 12% LOWER; filed a $100 million mixed securities shelf
Boxlight Corporation (NASDAQ: BOXL) 8.6% HIGHER; reported Q2 EPS of ($0.13), $0.01 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $9.7 million versus the consensus estimate of $6.45 million.
Dean Foods (NYSE: DF) 7.7% LOWER; JPMorgan analyst Ken Goldman downgraded from Neutral to Underweight with a price target of $6.00 (from $9.00).
NVIDIA (NASDAQ: NVDA) 5.1% LOWER; reported Q2 EPS of $1.94, $0.28 better than the analyst estimate of $1.66. Revenue for the quarter came in at $3.12 billion versus the consensus estimate of $3.1 billion. Q3 Revenue is expected to be $3.25 billion, plus or minus two percent (*** consensus is $3.34 billion).
Accuray (NASDAQ: ARAY) 5% HIGHER; reported Q4 EPS of ($0.01), $0.01 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $113.8 million versus the consensus estimate of $107.73 million. Accuray sees FY2019 EPS of $415.00-$425.00, versus the consensus of $411.20.
Applied Materials (NASDAQ: AMAT) 5% LOWER; reported Q3 EPS of $1.20, $0.03 better than the analyst estimate of $1.17. Revenue for the quarter came in at $4.47 billion versus the consensus estimate of $4.43 billion. Applied Materials sees Q4 2018 EPS of $0.92-$1.00, versus the consensus of $1.17. Applied Materials sees Q4 2018 revenue of $3.85-4.15 billion, versus the consensus of $4.46 billion.
Nutanix (NASDAQ: NTNX) 4.8% LOWER; Jefferies downgraded from Buy to Hold with a price target of $60.00.
DSW Inc. (NYSE: DSW) 4.7% LOWER; Susquehanna downgraded from Neutral to Negative with a price target of $22.00 (from $26.00).
Antares Pharma, Inc. (NASDAQ: ATRS) 4.6% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has approved Teva Pharmaceutical Industries, Ltd.s (Teva) epinephrine auto injector drug-device combination product indicated for emergency treatment of severe allergic reactions including those that are life threatening (anaphylaxis) in adults and certain pediatric patients. Our partner Teva filed an Abbreviated New Drug Application (ANDA) seeking FDA approval of the product as a generic substitute of Mylans branded product EpiPen®. Tevas drug-device combination product utilizes the Antares Pharma VIBEX® device and has been approved with an AP rating, defined as a therapeutically equivalent injectable aqueous solution and therefore fully substitutable to the EpiPen at the pharmacy.
Tesla, Inc. (NASDAQ: TSLA) 3.8% LOWER; CEO interview with New York Times
J. C. Penney (NYSE: JCP) 3.1% LOWER; Citi cuts price target to $0.50
Amicus Therapeutics (NASDAQ: FOLD) 2.5% LOWER; Chardan Capital Markets downgraded from Buy to Neutral with a price target of $15.00 (from $18.50).
Campbell Soup (NYSE: CPB) 2.1% LOWER; taps Goldman to examine sales of business units to pay down debt - CNBC
Deere & Co. (NYSE: DE) 1.8% LOWER; reported Q3 EPS of $2.59, $0.16 worse than the analyst estimate of $2.75. Revenue for the quarter came in at $9.29 billion versus the consensus estimate of $9.21 billion.
Zoe's Kitchen, Inc. (NYSE: ZOES) 1.7% LOWER; is postponing release of its fiscal second quarter 2018 results and its earnings conference call, which were scheduled for this afternoon. The conference call is being rescheduled for Friday, August 17, at 8:30 AM Eastern Time, and the Company intends to issue a press release with second quarter 2018 financial results that same morning, prior to the commencement of the conference call.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- After-Hours Stock Movers 05/10 (DDD) (NLS) (BRKS) Higher; (RCKT) (RXT) (LOTZ) Lower (more...)
- Omeros (OMER) Reports In-Line Q1 EPS, Revenues Beat
- Mesa Air Group (MESA) Tops Q2 EPS by 6c
Create E-mail Alert Related CategoriesSpecial Reports
Related EntitiesJPMorgan, Citi, Jefferies & Co, Susquehanna International Group of Companies, Tesla, Earnings, Pre-Open Losers, Pre-Open Winners, Chardan Capital Markets, Pre Market Movers, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!